The increasing number of people with advanced Alzheimer's disease (AD) represents a
significant psychological and financial cost to the world population. Accurate detection of the …

Since the establishment of the biomarker-based ATN (Amyloid/Tau/Neurodegeneration)
framework in Alzheimer's disease (AD), the diagnosis of AD has become more precise, and …

Background Because of high prevalence of Alzheimer's disease (AD) in low-and middle-
income countries (LMICs), there is an urgent need for inexpensive and minimally invasive …

Abstract Alzheimer's disease (AD), which mainly occurs in the elderly, is a
neurodegenerative disease with a hidden onset, which leads to progressive cognitive and …

Introduction Abnormal retinal changes are increasingly recognized as an early pathological
change in Alzheimer's disease (AD). Although amyloid beta oligomers (Aβo) have been …

A non-invasive and sensitive blood test has long been a goal for early stage disease
diagnosis and treatment for Alzheimer's disease (AD) and other proteinopathy diseases. We …

Background Subjective cognitive decline (SCD) is a target for Alzheimer's disease
prediction. Plasma amyloid-beta oligomer (AβO), the pathogenic form of Aβ in blood, has …

Alzheimer's disease (AD) includes the formation of extracellular deposits comprising
aggregated β-amyloid (Aβ) fibers associated with oxidative stress, inflammation …

Introduction Evidence strongly suggests that soluble oligomers of amyloid beta protein (oAβ)
help initiate the pathogenic cascade of Alzheimer's disease (AD). To date, there have been …

In this manuscript, we introduced a French EOAD patient in Korea who carried the presenilin-
1 (PSEN1) Glu318Gly mutations with four possible risk variants, including sortilin-related …